Abstract
Background:
Mycobacterium tuberculosis (Mtb) complex (MTBC) includes ten species that affect mammals and pose a significant global health concern. Upon infection, Mtb induces various stages in the host, including early bacterial elimination, which may or may not involve memory responses. Deciphering the role of innate immune responses during MTBC infection is crucial for understanding disease progression or protection. Over the past decade, there has been growing interest in the innate immune response to Mtb, with new preclinical models emerging.
Methods:
We conducted a systematic review following PRISMA guidelines, focused on innate immune mediators linked to protection or disease progression in animal models of MTBC infection. We searched two databases: National Library of Medicine and Web of Science. Two researchers independently extracted data based on specific inclusion and exclusion criteria.
Results:
Eighty-three articles were reviewed. Results were categorized in four groups: MTBC species, animal models, soluble factors and innate pathways, and other molecules (metabolites and drugs). Mtb and M. bovis were the only species studied. P2X7R receptor's role in disease progression and higher macrophage recruitment were observed differentially after infection with hypervirulent Mtb strains. Mice and non-human primates (NHPs) were the most used mammals, with emerging models like Galleria mellonella and planarians also studied. NHPs provided insights into age-dependent immunity and markers for active tuberculosis (ATB). Key innate immune factors/pathways identified included TNF-α, neutrophil recruitment, ROS/RNS responses, autophagy, inflammasomes, and antimicrobial peptides, with homologous proteins identified in insects. Metabolites like vitamin B5 and prostaglandin E2 were associated with protection. Immunomodulatory drugs targeting autophagy and other mechanisms were studied, exhibiting their potential as therapeutic alternatives.
Conclusion:
Simpler, physiologically relevant, and ethically sound models, such as G. mellonella, are needed for studying innate responses in MTBC infection. While insects lack adaptive immunity, they could provide insights into “pure” innate immune responses. The dissection of “pure,” “sustained” (later than 7 days post-infection), and trained innate immunity presents additional challenges that require high-resolution temporospatial analytical methods. Identifying early innate immune mediators and targetable pathways in the blood and affected tissues could identify biomarkers for immunization efficiency, disease progression, and potential synergistic therapies for ATB.
1 Introduction
In recent decades, there has been an increasing interest in the innate response mediators against members of the Mycobacterium tuberculosis (Mtb) complex (MTBC). MTBC groups ten genetically related species of the Mycobacterium genus that cause tuberculosis (TB) in different mammal species. Within MTBC, Mtb and M. bovis are the most significant species for human health to date (, ). Mtb is the leading infectious killer for humans, which generated an estimated close to 1.3 million deaths worldwide in 2023 (). On the other hand, M. bovis is the primary causative agent of bovine TB and represents a risk for humans and other mammal species due to its ability to infect a broad spectrum of hosts (, ).
Innate immunity is the body’s first line of defense against pathogens, present from birth, and characterized by non-specific responses that do not involve genetic rearrangement (). It aims to control infections either directly through effector responses or by activating adaptive immunity (, ). While much of our knowledge about innate immune responses to MTBC comes from in vitro and ex vivo studies, some findings have been inconsistent, for instance the role of neutrophils and the vitamin D during Mtb infection (–). Neutrophils’ ability to kill Mtb varies, depending on the cell of origin (mouse vs. human) or other unidentified factors (). Besides these inconsistencies, these short-lived cells present significant challenges during in vitro or ex vivo assays (–). Similarly, although vitamin D inhibits Mtb growth in vitro, its clinical use in TB treatment has not shown substantial improvement in patient outcomes (). These discrepancies highlight the difficulties in translating in vitro findings to clinical settings.
Early innate responses to Mtb are critical in determining the infection’s outcome in humans, with only 20-25% of individuals exhibiting signs of infection after being exposed to this pathogenic bacterium (). In some individuals, a combination of innate and adaptive immunity, or in others, the action of mostly (or solely) innate immunity are proposed to control the infection (–). For instance, close contacts of TB patients (exposed to the bacterium) never develop disease or exhibit delayed hypersensitive type IV response (PPD-negative). These “self-controlling” TB cases and non-infected contacts drive the hypothesis that some Mtb-infected people develop innate responses with a sterilizing activity against the bacterium (). This hypothesis has yet to be fully confirmed since recent studies have not found a protective innate response among PPD-negative contacts. However, this still does not exclude the possibility of unknown innate markers associated with early Mtb elimination and even “innate memory” responses that help in this matter (, ). While adaptive responses (led by T-cell immunity) are well-studied, they do not fully explain protection against TB, highlighting the importance of further research into innate immunity to find markers of protection or disease control.
Various preclinical animal models, including mice, non-human primates (NHP), and other vertebrates, have been used to study Mtb-host interactions. However, ethical concerns around animal research as well as the high cost and infrastructure associated, have led to increasing interest in alternative models, such as invertebrates. These invertebrate models hold potential for providing new insights into the Mtb-host interaction and expanding research options while acknowledging ethical concerns. Considering the importance of animal models in pre-clinical studies, we conducted a systematic review of recent findings towards innate responses found exclusively during in vivo infection with members of the MTBC, exploring the evolution and some limitations observed.
2 Methods
2.1 Study design
This systematic review aims to comprehensively analyze published peer-reviewed articles within the last decade to determine the molecules and pathways associated with innate responses in animal models infected with MTBC. We adopted the PICO (Population: animal models, Intervention: infection with an MTBC strain in the laboratory setting; Comparation: Group of non-infected animals, Outcome: innate response molecules associated with protection or disease progression) framework () to formulate the central question: What type of innate immune mediators (soluble factors and innate pathways) are commonly identified among different animal models that are either associated with protection or disease progression after MTBC infection? The collection of experimental studies and the analysis of their findings were focused on experimentally infected animals only and provided the most common and recently used animal models for MTBC infection. Our review also includes the description of novel host molecules associated with an early antibacterial response and potential limitations in this field. This review aims to provide state of the art information about the preclinical models used to study innate responses against Mtb and other members of the MTBC complex, extracting some commonalities, advantages and disadvantages, as well as some valuable findings in the most novel models used.
2.2 Search strategy and selection criteria
For the systematic search, two databases were consulted: the National Library of Medicine National Institutes of Health (PUBMED) and the Web of Science (WOS). The Medical Subject Headings (MeSH) terms selected were “Innate Immune Response,” “Mycobacterium tuberculosis,” and “Animal Model,” separated by the Boolean operator AND. The initial search was conducted on July 18, 2023, and the inclusion criteria were articles that:
were published in the last ten years,
described experimental data on animals,
reported animals infected with members of MTBC complex, and
evaluated innate responses.
We excluded articles focused only on in vitro, ex vivo, clinical studies, other infections (including other species of the Mycobacterium genera), studies that did not use live bacteria to infect the animals, reviews, opinions, meeting reports, and perspectives.
2.3 Study selection and data extraction
Two researchers (LMNR and CM) conducted the article search independently using the MeSH terms described above and extracted the articles obtained using Zotero and Endnote, respectively, following the referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (). The search was evaluated for duplicate entries, and every abstract was then analyzed for an initial application of the inclusion/exclusion criteria listed in the previous section. For most cases, the whole article was assessed in the initial screening, looking for the innate immune response findings derived from animal infections only. The total list was revised twice to manually extract all the information used in the qualitative and frequency analysis of four different categories: (i) MTBC species, (ii) animals used, (iii) soluble and membrane-associated factors and innate pathways, and (iv) other relevant molecules.
3 Results
3.1 Results of the search
After removing duplicates and applying inclusion and exclusion criteria, we initially selected 76 articles for the review, out of 274 articles collected for analysis. While reviewing the selected articles, we found seven additional publications that meet the inclusion criteria (some were part of the references in the initial selection), giving us 83 articles to review (Figure 1; Supplementary Table 1).
Figure 1
3.2 Synthesis and analysis of the reviewed articles
During the data extraction process, we focused specifically on innate immune responses observed in vivo following infection with live bacteria, excluding studies that used mixed approaches (like infecting animals and then evaluating responses only after ex-vivo stimulation of specific cell types). As an initial step, we identify the infecting bacteria, the animals and infection routes used to ensure the validity of the findings in the context of our PICO question (Figure 2). This review concentrates on early innate responses, as defined by innate immunity, but also included studies that measured responses weeks or even years after infection, particularly for investigating memory-like or trained immunity responses (
Figure 2

(A) Frequency of animals used in innate response studies against members of the Mycobacterium tuberculosis complex (MTBC), along with the infection routes reported for each animal model. (B) MTBC strains used in the reviewed articles, categorized by animal models. Since mice were the most commonly reported model, the lower section of the figure focuses specifically on MTBC strains used in mice. A total of 83 articles were evaluated. Note that some articles utilized more than one animal model (primarily mice and non-human primates), infection route, or strain, but no studies involving mixed infections were included. Figure created with Biorender.
Figure 3

Early and sustained innate responses found in animals with active TB. (A) Main responses associated with active disease. (B) Responses observed after immunization and after Mycobacterium tuberculosis complex (MTBC) infection in immunized animals (
Trained immunity occurs when pathogens or their components [pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs)] induce epigenetic changes, such as histone methylation, leading to non-permanent changes in inflammatory gene expression (
The present review does not intend to provide a hierarchy classification of the animal models studied based on which could be more relevant to replicating human ATB. Rather, it intends to provide major applications and limitations observed within each study type. Also, following our PICO question, we evaluate the main findings in terms of molecules and innate pathways, as well as their association with the clinical presentation of the disease.
3.2.1 MTBC species
The reviewed articles focused on two species from the MTBC: Mtb and M. bovis, including various genotypes, attenuated or hypervirulent mutants, and clinical isolates (Figure 2B). Additional searches for other MTBC members, such as M. africanum, M. canetti, M. caprae, M. microti, M. mungi, M. orygis, M. pinnipedii, and M. suricattae, did not yield any result. Mtb H37Rv, mostly used to infect mice, was the most frequent strain reported, followed by Mtb Erdman and M. bovis BCG. Thirty articles were excluded because they reported infections with species outside the MTBC, primarily M. marinum. While M. marinum is often used to study host-pathogen interactions in zebrafish (which develop granuloma-like structures similar to those in human TB) (
Different Mtb strains, such as H37Rv, CDC1551, and W-Beijing, were evaluated for their role in infections. Hypervirulent strains like W-Beijing, for instance, are known to cause severe pathology, including significant neutrophil infiltration and higher levels of necrosis (
Table 1
| Mutant Mouse strain | Factor studied | Major findings in the mutant mouse strain | Role in MTBC infection |
|---|---|---|---|
| Cish (-/-) ( | Cytokine-inducible SH2-containing protein (CISH2) | Increased bacterial burden in lungs and spleen in the first weeks of infection, with reduced levels of iNOs and TNFα, independent of neutrophil levels. | Protection |
| clecsf8 (-/-) ( | C-type lectin receptor (CLECSF8) | Increased lung inflammation, bacterial counts at 4 m.p.i, and mortality. CLECSF8 recognizes TDM and is anti-mycobacterial in mice. Significant increase of neutrophil infiltration in lungs 48 h.p.i with BCG, H37Rv, or Beijing. All proinflammatory cytokines evaluated and IL-10 were significantly increased after infection with H37Rv, but only TNF-α, IFN-γ, and G-CSF after BCG infection. | Protection |
| TNF (-/-) ( | Tumor necrosis factor (TNF) (during intracerebral infection) | Reduced antigen presentation capacity (↓MHCII CD80 and CD86 markers at 3 w.p.i) in macrophages and DCs, increased neutrophils and phagocytic cells recruitment with an unregulated inflammatory response and bacteria replication that resulted in higher mortality. | Protection |
| NsTNF (-/-) ( | Neuron-specific TNF (during intracerebral infection) | Resistant to infection as the wild type, and therefore NsTNF was considered functionally redundant to TNF. | No effect observed |
| TCRβ (-/-) ( | T cell receptor β (TCRβ)** | Increased expression of cell-surface activation markers (↑MHCII, CD86, CD80, and CD40), cytokines (↑TNF-α, IL-12, IL-6), chemokines (↑CXCL8, 9 and 11, CCL5, and CCR2), and ↑MMP1; overall associated with tissue damage. | Protection |
| Park2 (-/-) ( | E3 Ubiquitin Protein Ligase (Parkin) | Unable to control intracellular bacteria and rapidly succumb after infection (at 85 d.p.i). Parkin is essential to early control of intracellular mycobacteria in lungs and other organs. | Protection |
| Cramp (-/-) ( | Cathelicidin-related antimicrobial peptide (Cramp) | More severe lung and spleen lesions, and higher bacterial burden at 56 d.p.i. KO animals succumbed earlier to Mtb infection (at 69 d.p.i). | Protection |
| bhlhe40 (-/-) ( | Transcription factor basic helix-loop-helix family member e40 (bhle40) | Higher bacterial loads in the lung, neutrophil-dominated inflammation (since 21 d.p.i), and early mortality (at 40 d.p.i) after Mtb infection; in a phenotype dependent on IL-10 levels. Blhe40 controls the IL-10 expression. | Protection |
| IL-21R (-/-) ( | IL- 21 Receptor | IL-21 acts as a potent inhibitor of an IL-17A-producing γδ T-cell subset that mediates neutrophil-dependent inflammatory responses during BCG infection. | Not evaluated |
| P2X7R (-/-) ( | P2X purinoceptor 7 | Disease attenuation with moderate lung pathology, leukocytes infiltration (on 28 d.p.i) and delayed in mortality in an ATP-dependent manner after infection with the hypervirulent Beijing Mtb strain only. | Disease progression (with hypervirulent strains). |
| DuoX1 (-/-) ( | Dual oxidase 1 (Duox1) | Increased the pro-inflammatory cytokine in the airway at day 30 post-Mtb infection, without differences in bacterial counts or lung pathology. | No effect observed |
| fcgrt (-/-) ( | Neonatal Fc Receptor (FcRn) | Increased levels of CD103+ DCs population pre-infection and at 14 d.p.i, with a later decrease of neutrophils, monocyte and macrophages at one m.p.i in the granulomas. This effect was concomitant to transient reduction in CFU counts. | No effect observed |
| Mif−/− ( | Macrophage migration inhibitory factor (MIF) | Decreased IL-6, TNF-α, IL-10, and IL-12 and increased IFN-γ, G-CSF, MIP-2 in lungs at 2 m.p.i. Larger lesions, higher bacterial counts and greater accumulation of neutrophils in the lung with high MPO+, resulting in faster mortality compared to WT after infection. | Protection |
| NOD/SCID/IL-2Rγ-/- (NSG) ( | Human engrafted macrophages in NSG mice | Human macrophages in severely immunodeficient mice support BCG growth better than murine macrophages from C57BL/6 mice at 4 w.p.i. | Higher susceptibility |
| B6 ΔdblGata and B6 PHIL (eosinophil-deficient) ( | Eosinophils | Downregulation of genes involved in short-chain fatty acid, endocannabinoid, and arachidonic acid metabolism and neurological processes at 90 d.p.i. compared to WT. KO animal exhibited higher bacterial loads after 30 d.p.i. and died earlier. No changes observed in lung-resident immune cells or pathology. | Protection |
| Atg5fl/fl-Lysm-cre ( | Autophagy related gene 5 (ATG5) | Increased bacterial load in lung, severe lung inflammation with large lesions since 3 w.p.i. Mutant animals died at 40 d.p.i. ATG5 in contrast to other ATG genes is essential to control Mtb infection. | Protection |
| Ifnar(-/-) ( | Type I IFN receptor and αGM-CSF | Blockage of GM-CSF causes excessive formation of NETs, increased CFU counts and lung pathology at 21 d.p.i in WT. This process was dependent on Type I IFN responses, since this trend was mitigated in the KO animal. Type I IFN induced neutrophil response was linked to disease exacerbation. | Higher susceptibility |
Examples of genetically modified mouse strains used for the evaluation of innate responses against Mycobacterium tuberculosis complex (MTBC)*.
*Evaluating innate responses measured after in vivo infection only, excluding any ex-vivo post stimulation findings.
**Although this receptor is part of adaptive immunity, innate responses were also evaluated in this knock out (KO) strain and summarized here. iNOs, inducible nitric oxide synthase; TNF, tumoral necrosis factor; TDM, trehalose dimycocerosate; BCG, Bacillus Calmette-Guérin; IL-, interleukin; IFN, interferon; G-CSF, Granulocyte colony-stimulating factor; MHC, Major Histocompatibility Complex; DCs, dendritic cells; w.p.i, weeks post-infection; CXCL, Chemokine (C-X-C motif) ligand; CCL, Chemokine (C-C motif) ligand; CCR2, C-C chemokine receptor type 2; MMP, matrix metallopeptidase; d.p.i, days post infection; m.p.i, months post infection; MIP-2, Macrophage inflammatory protein 2; MPO, Myeloperoxidase; GM-CSF, Granulocyte-monocyte colony-stimulating factor; NOD, non-obese diabetic; SCID, severe combined immune deficiency; B6 ΔdblGata, B6 mice with a deletion of a high-affinity GATA–binding site in the GATA-1 promoter; B6 PHIL, Transgenic mice that express cytocidal diphtheria toxin A under the eosinophil-specific EPX promoter; NETs, neutrophil extracellular traps; WT, wild type.
Strain-specific responses were also observed in BCG-vaccinated C3Heb/FeJ mice subsequently infected with the Mtb Beijing strain. Henao-Tamayo et al. found a significant reduction in granulocytic influx to the lungs 25-50 days post-infection, which was accompanied by lower bacterial counts and less lung necrosis at the same time points (
3.2.2 Animals used and significant findings in each model
Animal models used in the 83 evaluated articles are summarized in Figure 2A, highlighting mammalian species as the most frequently used. Similarly to previous reviews focused on animal models of MTBC infection (
3.2.2.1 Mouse
Many important discoveries in the innate response against Mtb (i.e., role of TNF-α, IFN-γ, IL-12, among others) have been obtained in the mouse model (
Under the mouse background (BALB/c, C57BL/6, and C3HeB/FeJ, also known as Kramnik), transgenic and knock-out strains for specific genes have been used as models to evaluate different innate immune response mediators in the articles reviewed (Table 1). These different genetic mice also reflect different degrees of susceptibility to Mtb infection. C57BL/6 mice are generally considered more resistant to Mtb infection than BALB/c mice, and both mice do not develop necrotic lung lesions, a pathology hallmark of human TB (
3.2.2.1.1 Study of innate immune responses in the context of metabolic comorbidities
The mouse model was used to evaluate chronic comorbidities, specifically type 2 diabetes (T2D), which negatively impacts Mtb infection outcomes in humans (
Table 2
| Molecule | General trend observed regarding MTBC infection | Animal (s) | References |
|---|---|---|---|
| Tumoral necrosis factor alpha (TNF-α) pathway | |||
| TNF-α | Shared trend with IFN-γ: ↓ in lung and liver of diabetic mice at 1 d.p.i with Mtb. ↑ expression in MAIT cells from BAL at 3 w.p.i.in NHP that develop LTBI vs ATB. ↑ after HDAC-6 inhibition by Tubastatin at 5 d.p.i with H37Ra, associated with reduced CFU counts in mice. ↓ in the intestine of microbiota disrupted mice 10 w.p.i. | Mice NHP Rabbits | ( |
| Nf-kB | ↑in S1-P treated animals that exhibit Protective immunity against Mtb | Mice | ( |
| ROS and RNS production in phagocytes | |||
| iNOs/NOS2 | ↑ in ATB. ↑ in rabbits supplemented with iron at 8 w.p.i. with no effect in bacterial burden or lung pathology. ↑by type I IFN, S1-P (in macrophages) and CISH. ↑ after Ipr1 recombinant BCG vaccination in mice and associated with protection against Mtb. ↓ in lungs of transgenic mice overexpressing SMAR1 since 6 w.p.i. | Mice NHP Rabbit | ( |
| NCF4 | ↑ after Ipr1 recombinant BCG vaccination and associated with protection against Mtb. ↓ bacterial load and pathology. | Mice | ( |
| Myeloperoxidase | Present in NETs. | Guinea pig | ( |
| Autophagy | |||
| LC3 | Fundamental in TB elimination and ↓disease severity | Planarians Mice | ( |
| ATG5 | Essential to limit inflammation driven by PMN | Mice | ( |
| MORN2 | Promote LC3-mediated autophagy | Planarians | ( |
| Complement | |||
| C3 | ↑ in PBMC from oral mucosa of oral-vaccinated animals with ↓ lesion scores (measured in tonsils, lymph nodes, lung) at ~4 m.p.i. | Wild boar | ( |
| Sfpd | Activate the complement. ↑ after Ipr1 recombinant BCG vaccination/↓ bacterial load and pathology | Mice | ( |
| Neutrophil recruitment | |||
| MMP-9 | Excessive inflammation/tissue damage. Induce NETs. ↑ after loss/blockage of GM-CSF. | NHP Mice | ( |
| S100a6/S100a8/S100a9/Cd17, CXCR2 | ↑ in lungs and blood after loss/blockage of GM-CSF. ↑bacterial growth and promotes disease severity, independent of IFN-γ. | Mice | ( |
| MMP-8 | Excessive inflammation/tissue damage. Induce NETs. ↑ after loss/blockage of GM-CSF. | Mice | ( |
| MMP-1 | Tissue damage/↑ in TCRβ−/− | Mice | ( |
| Elastase | Present in NETs | Guinea pig | ( |
| Prg2 (mostly found in eosinophils, but also in neutrophil degranulation) | ↑ after Ipr1 recombinant BCG vaccination/↓ bacterial load and pathology | Mice | ( |
| NETs containing DNA and histones | Rapid but low effect response in Mtb killing | Guinea pig Mice | ( |
| Inflammasomes | |||
| Caspase-1 | Inflammatory response and ↑in disease progression and TB pathology | NHP Mice | ( |
| NLRP3 | Part of the inflammasome complex. Cytosolic PRR sensing RD1 Mtb components (Esat 6). Inhibited by miR-20b. ↑Transcripts in lungs of vaccinated animals | Wild boar Mice | ( |
| AIM2 | DNA cytosolic sensor ↑ in ATB | NHP Mice | ( |
| Antimicrobial peptides | |||
| LL37 | cause ↓ bacterial load/pneumonia ↑pro-inflammatory response | Mice | ( |
| mβD and HβD−3 and mβD−4 | cause ↓ bacterial load/pneumonia ↑pro-inflammatory response | Mice | ( |
| Cecropin-A, A1 and D-like | ↑ in BCG infected | G. mellonella | ( |
| HAMP | Show temporal changes after iron supplementation in ATB | Rabbit | ( |
| RegIII-γ (Regenerating islet-derived lectins) | ↓ in small intestine of microbiota disrupted mice at 10 w.p.i. | Mice | ( |
| Toll-like (TLR) receptor cascades | |||
| TLR4 | ↑ antibacterial effect when activated with LPS and used in junction with rifampicin and NOD-2 ligand. ↑ in TCRβ−/− mice after Mtb infection. ↑ after Ipr1 recombinant BCG vaccination. | Mice | ( |
| TLR2 and TLR9 | Both can be dispensable for IL-12 production and protective responses against Mtb. ↑after Ipr1 recombinant BCG vaccination. ↑ in TCRβ−/− mice after Mtb infection. TLR2 only: ↓ in lungs from infected mice with disrupted gut microbiota at 10 w.p.i. | Mice | ( |
| Myd88 | Control Mtb growth, restore inflammatory cytokine, signal of active innate response post-vaccination | Wild boar Mice | ( |
| TRAF6 | ↑ levels associated with TB signs and tissue damage, ↑ in TCRβ−/− mice | Mice | ( |
| TRIF | Localized lung response/↑ in cases with less pathology | Wild boar | ( |
| Interferon (IFN) signaling | |||
| IRF1 IRF2 IRF4 IRF7 | IRF1 ↑ in ATB IRF2 ↑ in severe TB. IRF4 ↓when ↑ TB signs IRF7 ↓in vaccinated animals and associated with disease severity | NHP Rabbits | ( |
| IFN-γ | ↑ in BAL of in mice treated with Colexib after 15 d.p.i, associated with higher phagocytic activity and reduced CFU counts. (other shared with TNF-α, see first section of the table) | Mice NHP Rabbit | ( |
| STAT1 | ↑ in virulent HN978 infection | NHP Rabbit | ( |
| JAK2 | ↑ in ATB | NHP | ( |
| SOCS1 and 3 | ↓levels associated with TB signs and tissue damage, ↓ in TCRβ−/− mice | Mice | ( |
Molecules associated with main innate pathways reviewed during Mycobacterium tuberculosis complex (MTBC) infection.
NHP, non-human primates; IFN, Interferon; d.p.i, days post infection; MAIT, mucosal-associated invariant T; BAL, bronchoalveolar lavage; TB, tuberculosis; LTBI, latent TB infection; ATB, Active TB; HDAC, Histone deacetylase; w.p.i, weeks post-infection; S1-P, sphingolipid sphingosine-1-phosphate; ROS, Reactive oxygen species; RNS, Reactive nitrogen species; iNOs/NOS2, inducible Nitric oxide synthase/Nitric Oxide synthase 2; CISH, Cytokine-inducible SRC homology 2 (SH2) domain protein; BCG, Bacillus Calmette-Guérin; SMAR1, Scaffold/matrix attachment region binding protein 1; NCF4, Neutrophil Cytosolic Factor 4; Ipr1, intracellular pathogen resistance gene 1 from mouse; NETs, Neutrophil extracellular traps; LC3, Microtubule-associated protein 1A/1B-light chain 3; ATG5, Autophagy related 5; PMN, polymorphonuclear leukocytes; MORN2, Membrane Occupation and Recognition Nexus repeat-containing-2; C3, Complement C3 protein; PBMCs, Peripheral Blood Mononuclear Cell; m.p.i, months postinfection; Sfpd, Surfactant protein D; MMP, Matrix metalloproteinases; GM-CSF, Granulocyte-monocyte colony-stimulating factor; S100a6, S100 calcium-binding protein A6; S100a8 (also known as MRP8) and S100a9, S100 calcium-binding protein A8 and A9 respectively, together form a complex called calprotectin; CXCR, chemokine receptor CXC; TCR, T-cell receptor; Prg2, Proteoglycan 2; NLRP3, NOD-like receptor (NLR) pyrin domain-containing protein 3; AIM2, DNA cytosolic sensor “absent in melanoma 2”; LL37, cathelicidin; mβD and HβD, mouse and human beta-defensins; HAMP, hepcidin antimicrobial peptide; LPS, lipopolysaccharide; NOD, nucleotide oligomerization domain; IL, interleukin; Myd88, myeloid differentiation primary response 88; TRAF6, Tumor necrosis factor receptor-associated factor 6; TRIF, Toll/IL-1R domain-containing adaptor-inducing IFN-β; IRF, Interferon regulatory factor; STAT, signal transducer and activator of transcription; JAK, Janus kinase; SOCS, Suppressor of cytokine signaling.
3.2.2.1.2 Trained immunity
Nucleotide-binding oligomerization domain-like receptor (NOD)-associated trained immunity response was studied in mice by Bricket et al. and was not associated with the early anti-mycobacterial mechanisms induced by BCG. In this study, mice were infected 7 days after receiving the BCG vaccine, detecting similar reductions in lung bacterial counts in both NOD1 and NOD2 deficient mice, as well as in wild-type (WT) mice. At 7 days post-vaccination, higher levels of circulating monocytes (CD11b+F4/80+) and neutrophils were recruited to the lungs, and these were sufficient to control the infection in live-BCG vaccinated mice. This response was accompanied by increased levels of TNF-α and IFN-γ in the lungs. However, the protective innate immune response was independent of natural killer (NK) cells and IFN-γ levels and was instead dependent on neutrophils (
Steigler et alfound significant increased levels of innate lymphoid cells (ILCs) secreting high levels of IFN-γ in the lungs, four weeks after intranasal BCG vaccination. The immune response found using the intranasal vaccination was stronger compared to other administration routes, such as intradermal vaccination (
Additional knock-out (KO) mouse strains allowed the study of specific mediators, either soluble molecules or receptors, to validate their roles in the innate response against MTBC in pulmonary or cerebral infection. Table 1 summarizes the main findings for some of these KO mouse strains.
3.2.2.2 Non-human primates
Macaca mulatta (rhesus macaques, RM) and Macaca fascicularis (cynomolgus macaques, CM), were the second most used models to study TB, due to their ability to closely mimic human TB and immune responses. NHPs are the preferred model to investigate TB vaccines and pathogenesis. While NHP models are highly informative, they have limitations, including high costs, specialized infrastructure, and ethical concerns (
Table 3
| NHP species (authors) | Factor studied | Major findings | Role in MTBC Infection |
|---|---|---|---|
| RM (Bohrer et al.) | Eosinophils ( | Heterogeneous infiltration of eosinophils, mainly located at the outer rim of the granuloma with evidence of degranulation prior cell death (significant high expression of CD63 and diffuse eosinophil peroxidase in the necrotic core). CD63 expression in the granuloma inversely correlated with bacterial burden at 7-12 w.p.i, but CD63 expression was highly variable even in granulomas from the same animal. Also, there was no correlation between eosinophil abundance and bacterial load. | Inconclusive (in this model) |
| RM (Sarfas et al.) | Classical monocytes (CD14+CD16-), granulocytes, eosinophils and CD16+CD56+ NK after BCG comparing neonatal (neo) vs adult animals ( | BCG vaccination induces in neo: ↑eosinophils at ~20 weeks p.v. ↓ granulocytes from ~12 weeks p.v. ↓classical monocytes at ~20 weeks p.v. ↓monocytes and NK-producing IFN-γ and TNFα and ↑IL-2 producing NK since week 20 p.v. | Inconclusive (only responses measured after BCG vaccination) |
| RM (Singh et al.) | Poly-morphonuclear myeloid-derived suppressor cells (PMN-MDSCs) ( | PMN-MDSCs expressing Ki67, IDO1, IL-10, MMP-9, iNOS, and PD-L1 were higher in the periphery of granuloma of ATB vs LTBI animals at 9 weeks p.i. | ATB, disease progression. |
| RM (Bucsan et al.) | GrB+IFN-γ+IL-17+TNF-α+ Mucosal-associated invariant T (MAIT) cells ( | GrB+IFN-γ+IL-17+TNF-α+ MAIT cells were specifically higher in BAL of animals that control the Mtb infection at 3 w.p.i. | Associated with LTBI (controlled) rather than with ATB |
| RM (Hansen et al.) | IFN-response-associated genes (IRF7) and the inflammasome components AIM2 CASP1, and STAT1) ( Neutrophil degranulation markers (MMP8, OLFM4 and CD52) ( | Transcript blood levels of IRF7, AIM2, STAT1, and CASP1 at 28 d.p.i were correlated disease progression and were strongly reduced in the vaccinated animals, based on bacterial load and pathology score. Animals with a “protective profile” (based on bacterial load and pathology score) have higher levels of genes associated with neutrophil degranulation markers in blood immediately pre-Mtb challenge. | ATB and progression Protection |
| CM (Gideon et al.) | Gene clusters related to complement regulation, hematopoiesis, IFN responses, inflammation, and coagulation/platelet response. Triggering receptor expressed on myeloid cells (TREM)-1 signaling ( | Transcriptomic analysis revealed increased expression in these gene clusters, especially IFN signaling, JAK-STAT pathway, and dendritic cell maturation, since day 20 p.i in ATB. TREM-1 signaling associated transcripts in blood were associated with higher inflammation in ATB at 90-180 d.p.i. | ATB Higher extent of lung inflammation |
| CM (Javed et al.) | FOS, Kruppel-like factor 2 (KLF2), IL7R and IL8 ( Type II IFN signaling and other IFN response factors (IRFs) (including the genes SOCS3, JAK2, STAT1, SPI1, IRF1, IRF2, IRF4, IFNGR1, and GBP1) ( | Upregulated in the first 2 weeks and then stayed downregulated in cases of ATB until week 6. This transcriptomic profile may be associated with increased apoptosis after 2 w.p.i. and stimulation of T cell response and an M2 phenotype. The upregulation of these genes was associated with ATB, some of them since 2-6 w.p.i compared to pre-infected stage. Additionally, Mauritian macaques were more susceptible to develop severe TB compared to the Chinese lineage. Downregulation of SOCS3, IRF4 and IFNβ1 with upregulation of IRF4 correlated with signs of disease. | Early marker of ATB (exposure to Mtb) Markers of disease progression. |
Reviewed non-human primate (NHP) innate responses after Mycobacterium tuberculosis complex (MTBC) infection*.
*Evaluating innate responses measured after in vivo infection only, excluding any ex-vivo post stimulation findings. RM, Rhesus Macaques; CM, Cynomolgus Macaques; w.p.i and d.p.i, weeks post-infection and d.p.i respectively; p.v, post-vaccination; NK, natural killers; BCG, Bacillus Calmette-Guérin; IFN, interferon; TNF, tumoral necrosis factor; IL, interleukin; Ki67, cellular marker for proliferation discovered in the city of Kiel and with the cell clone 67; IDO1, indoleamine 2,3-dioxygenase; MMP-9, matrix metallopeptidase 9; iNOs, inducible nitric oxide synthase; PD-L1, programmed death-ligand 1; TB, tuberculosis; ATB, Active TB; LTBI, Latent TB infection; GrB, Granzyme B; AIM2, DNA cytosolic sensor “absent in melanoma 2”; CASP, caspase; STAT, signal transducer and activator of transcription; OLFM4, Olfactomedin 4; JAK, Janus kinase; SIV, Simian immunodeficiency virus; FOS, Finkel-Biskis-Jinkins osteosarcoma, member of the AP-1 (activator protein-1) family of inducible transcription factors; SOCS, Suppressor of cytokine signaling; SPI1, SPI-1 Proto-oncogene, transcriptional factor also known as also known as PU.1; IFNGR1, Interferon gamma receptor 1; GBP1, Guanylate-binding protein 1.Symbol ↑ stand for increased and for symbol ↓ stand for decreased.
3.2.2.2.1 Innate responses in NHP with ATB vs LTBI
The NHP model is valuable for studying innate immune responses in the context of active TB (ATB) and latent TB infection (LTBI) (
ATB and LTBI outcome in CM were associated with early differences in the blood transcriptomic profile. Gideon et al. reported an increased transcriptomic blood signature in CM as early as 20-30 days d.p.i. that was linked to ATB (Table 3). Interestingly, LTBI animals showed an early increased IFN response at 7 d.p.i., which was reversed by 30 d.p.i. Overall, the transcriptomic profiles of ATB and LTBI in CM were similar to those observed in humans, though LTBI profiles in CM were more heterogeneous and less intense (
Javed et al. reported a temporal gene expression analysis in the blood of CM following Mtb infection, using a human genomic oligonucleotide microarray to identify biomarkers for ATB. This group identified gene clusters based on expression changes between pre-infected and infected animals over a 6-week period, described in Table 3 (
3.2.2.2.2 Innate responses following BCG vaccination discriminated by age
Sarfas et al. evaluated the immune responses of neonatal-vaccinated (neo-BCG) RM versus adult-vaccinated (ad-BCG) RM. They assessed systemic responses from 12 weeks to 3 years post-vaccination in neonatally vaccinated animals and at 20 weeks post-vaccination (p.v) in adults (
Interestingly, eosinophils were also studied in the context of MTBC infection in RM and mice (
3.2.2.3 Other mammals
Rabbits were reported by two articles that evaluated pathological features and transcriptional differences in innate-associated genes after external stimuli (
Subbian et al. found transcriptional differences in 14 genes at 3 hours post-infection with greater recruitment of macrophages and polymorphonuclear leukocytes (PMN) (with higher myeloperoxidase activity) and cavitary disease more like human active TB in the lungs of rabbits infected with HN878 compared to those infected with CDC1551. Overall, pathways involved in macrophage activation, fMLP (N-formyl-Methionyl-Leucyl-Phenylalanine)-stimulation or PMN recruitment and activation were upregulated after HN878 versus CDC1551 infection (Figure 3A). Some of the genes with increased expression include TNF, CXCL10, STAT1, IL1A, SPP1, CCL4, CCL2, IRF5, CD38, while reduced expression of IL4R, CAV1, TGFB2, IL18, and CD36 were observed (
Cattle infected with either M. bovis BCG or AF2122/97 were used as a model to study trained immunity (
The second article by Edmans et al. revealed a MAIT cell population in the blood that showed higher perforin expression two-weeks after M. bovis infection without changes in the number of these cells. This high perforin expression was seen mainly in animals with TB lesions (
Guinea pigs develop necrotic core granulomas, and their macrophages exhibit surface CD1b and CD1c, making them a beneficial small animal model for replicating human TB (
Wild boars were orally vaccinated with a heat-inactivated M. bovis strain and then infected with the same (viable) strain. Beltrán-Beck et al. evaluated the transcriptomic responses post-vaccination in the PMN of the oral mucosa and serum and then after infection in vaccinated animals. Some differences were noted in the complement and inflammasome responses post-vaccination, but only C3 mRNA levels remained after M. bovis infection, which was associated with reduced pathology (Figure 3B) (
3.2.2.4 Invertebrates
In recent years, invertebrate animal models such as the insect Galleria mellonella (
3.2.2.4.1 Galleria mellonella
The larvae of Galleria mellonella (greater wax moth) were used to assess infection by injecting the bacteria into the hemocoel(Figure 2A). This model has a simple body structure and ability to tolerate human body temperature, which allows the identification of components of innate responses that are shared with more complex animals, including cells, soluble factors, cell receptors, physical barriers, and processes (like phagocytosis, cell adhesion, redox responses, and others) (
Pathologically, G. mellonella larvae exhibit granuloma-like structures (called nodules) in their fat body with infected hemocytes (insect immune cells) (
3.2.2.4.2 Planarian species
Planarian species, specifically D. japonica and S. mediterranea, were explored as a novel model for studying Mtb infection. These planarians were infected directly by exposing them to liver homogenates mixed with Mtb. However, the study found that planarians could resist Mtb infection, as no viable bacteria were recovered after nine days post-infection (
3.2.3 Soluble and membrane-associated factors distributed in innate pathways
This section aims to provide information about the different factors (soluble and membrane-associated) studied by classifying them in different immunological pathways. Some pathways contain mediators acting on both innate and adaptive responses, like IL-21 or IFN-γ. However, only specific findings in the evaluation of innate responses were selected. For instance, IL-21 was evaluated as part of γδ T-cell response (
3.2.3.1 Tumoral necrosis factor alpha (TNF-α) pathway
One of the central and most frequently identified factors in these reviewed articles was the cytokine TNF-α that was reported in articles using mice (
3.2.3.2 ROS and RNS production in phagocytes
Reactive oxygen species (ROS) and nitrogen species (RNS) are essential components of the antimicrobial system, produced mainly by macrophages (
Neutrophil cytosolic factor 4 (NCF4) is a component of the NADPH oxidase complex, which is predicted to be involved in the production of O2-, via NADPH oxidase 2 (
Lastly, the production of ROS by lung-residing myeloid cells (primarily PMN and AM) in mice was hampered by the early action of platelets that reduced the availability of these cells by forming aggregates in the lung by 21 d.p.i (independently of their canonical activation, by cyclooxygenase (COX)-1, glycoprotein IIb/IIIa or the ADP-receptor P2Y12). This effect was confirmed by reduced bacterial load and lung pathology, as well as increased survival following platelet depletion around the onset of inflammation at seven d.p.i, but not before the infection (
3.2.3.3 IFN signaling
There are three types of IFNs: Type I (mainly IFN-α, -β, and others), Type II (IFN-γ), and Type III (IFN-λ). Reduced levels of IFN-γ were reported in diabetic mice as early as 24 h.p.i, that were exhibiting a dysregulated immune response with increased bacterial burden and inflammatory lesions (Figure 3A) (
IFN regulatory factors (IRF 1, 2, 3, 4, 5, and 7) showed a diverse response during Mtb infection. IRF7, among other innate transcriptional signatures from PMB cells in the blood, were correlated with the extent of disease and were strongly reduced in the vaccinated RM that exhibited Mtb control and reduced pathology (Table 3) (
3.2.3.4 Neutrophil recruitment
Neutrophils can internalize bacteria and activate inflammatory and effector responses, by the action of mediators like myeloperoxidase, elastase, and the production of NETs. As it was discussed earlier, neutrophils generate one of the earliest responses in the guinea pig (Figure 3, Table 2); however, they were ineffective at eliminating Mtb (
Other proteins also associated with this pathway are described in Table 2. Among those, proteolytic matrix metalloproteinases (MMP) participate in the degradation of the lung extracellular matrix components, with the subsequent Mtb spread. These proteins have been proposed as biomarkers of ATB disease (
The dual role of neutrophil described in the reviewed articles is represented by excessive inflammation in acute phase after infection (probably bacterial dose/strain-dependent) (
3.2.3.5 Inflammasomes
The inflammasome is a complex consisting of a sensor (such as a cytosolic pattern recognition receptor or PRR), an adaptor, and an effector (pro-caspase-1) proteins that, when activated, cleaves pro-inflammatory cytokines essential for MTBC control (138, 139). We found articles describing two types of inflammasome receptors: “NOD-like” receptor (NLR) pyrindomain-containing protein 3 (NLRP3) and the DNA cytosolic sensor “absent in melanoma 2” (AIM2) (Table 2). In mice, NLRP3 interacts with the Mtb Esat-6 protein and influences the expression of IL-18 and IFN-γ (94). In addition to mice (94,
Figure 4

Macrophage receptors and soluble factors identified in response to Mtb complex in the reviewed articles.A. Cytokines, chemokines and receptors identified in the reviewed articles mostly associated with M1 macrophages. (B) Intracellular and endosomal receptors. Some of the recognized molecules (from Mtb or the host) are written in blue in panels (A, B), including TDM: trehalose dimycocerosate (Mtb), ATP: Adenosine triphosphate released from host damaged cells, RD-1 Mtb: region of difference 1, present in virulent Mtb strains, DNA: self (host) and bacterial DNA, NG-MDP: Mycobacterial N-glycolylated muramyl dipeptide. IFN, Interferon; GM-CSF, Granulocyte-monocyte colony-stimulating factor; MIF, Macrophage migration inhibitory factor; IL, interleukin; TGF, Transforming Growth Factor; S1-P, sphingolipid sphingosine-1-phosphate; TLR, Toll-like receptor; iNOS, inducible nitric oxide synthase; IFNGR, Interferon-gamma receptor; MINCLE, Macrophage inducible C-type lectin, also known as CLEC4E; TREM, Triggering receptor expressed on myeloid cells; P2X7R, P2X purinoceptor 7; MHC, Major histocompatibility complex; MCL, macrophage C-type lectin; MCP-1, monocyte chemotactic protein-1; MIP-1α, Macrophage inflammatory protein-1α; CXCL, chemokine (C-X-C motif) ligand; CCL, C-C chemokine ligand; SOCS, Suppressor of cytokine signaling; MMP, Matrix metalloproteinase; miR-20b, microRNA 20b; NLRP3, NOD-like receptor (NLR) pyrin domain-containing protein 3; AIM2, DNA cytosolic sensor “absent in melanoma 2”; NOD, Nucleotide oligomerization domain. Macrophage phenotype classification done following (140–143). Created with BioRender.com.
Another inflammasome-related PRR is the AIM2-like receptor. Kuptz et al. demonstrated that NLRP3 rather than AIM2 was involved in the activation of IL-18 in mice (94). In NHP (RM), AIM2 was increased in animals with active TB and reduced in vaccinated animals that showed Mtb control (no signs of granulomatous disease) (Table 3) (
3.2.3.6 Autophagy
More than 30 autophagy-related genes (ATGs) and other players, such as the microtubule-associated protein 1A/1B-light chain 3 (LC3), perform this innate protein degradation and regulatory mechanism in mammals. The activation of these proteins results in the membrane invagination of the bacteria, its products, or even damaged self-organelles. There is also a non-canonical autophagy known as LC3-associated phagocytosis (LAP), with the participation of PRR, independently of autophagosome formation (144). Deficient ATG5 mice exhibit more severe inflammation and succumb earlier to the infection (Table 1) (
LC3 participates in the autophagosome maturation and has two recognized isoforms: a cytosolic (LC-I) and a membrane-associated isoform (LC3-II, that is LC-3 conjugated to phosphatidylethanolamine) (145). LC3-II, regularly measured as marker of autophagic activity, was found increased in M. bovis infected mice after treatment with nilotinib (also discussed in section 3.2.5) (
3.2.3.7 Antimicrobial peptides
Increased antimicrobial peptides were reported in the early response to MTBC infection, which was more prominent when a hypervirulent strain infected the host (
In the rabbit, the antimicrobial peptide HAMP was studied, which is also known to regulate systemic iron. In this study, HAMP levels in the lung were upregulated after 8 weeks post-Mtb infection in animals supplemented with iron without affecting bacterial load (
3.2.3.8 C-type lectin receptors
These groups of PRR were represented in the reviewed articles mainly by the Macrophage inducible C-type lectin receptor (MINCLE) and macrophage C-type lectin (MCL). Macrophages and DCs express MCL that recognize Mtb TDM (Trehalose 6,6’-dimycolate). Reduced MCL levels were linked to increased inflammation, bacterial burdens, and mortality in the mouse model (Table 1) (
3.2.3.9 Toll like receptor
We found three TLRs in our reviewed articles: TLR2, 4, and 9. Significant findings related to these TLRs and other molecules participating in this innate pathway are described in Table 2. The activation of TLR4 can be dependent or independent of myeloid differentiation primary-response protein 88 (MyD88). MyD88 is fundamental to clear MTBC infection. The reactivation of MyD88 signaling in myeloid cells (macrophages and DCs) during M. bovis BCG infection is sufficient to control pathogen growth and reinstate local inflammatory cytokine production (IL-12p40, IFN-γ, and IL-1β in lungs) in mice (
3.2.3.10 Fc gamma receptors (FCGRs)-dependent phagocytosis
This phagocytic receptor binds to the Fc portion of immunoglobulin G (IgG). One article evaluated the neonatal Fc receptor (FcRn) in a KO mutant mouse strain (Table 1). Mtb-infected mice lacking FcRn had a reduced neutrophil infiltration in Mtb-infected lungs, concomitant to reduced bacterial burden and pathology. Because of the absence of FcRn reduced the capacity of CD103+ DCs to eliminate bacteria, other phagocytic cells may be driving the Mtb elimination and contributing to the low pathology profile observed (
3.2.3.11 Immunoregulatory interactions between lymphoid and non-lymphoid cells
In this pathway, we have grouped the different IL observed in four mammalian species (Table 4) and the triggering receptors expressed on myeloid cells (TREM)-1. A high frequency of articles reporting IL and other cytokines and chemokines could be explained by their relevance in the inflammatory responses generated after MTBC infection, the availability of analytical methods (ELISA, Luminex®, flow cytometry), and reagents that allow the multiplexed study of these molecules, particularly in the mouse model. In the remaining animal models, IL and other cytokines were primarily studied using gene expression analysis, either by using qRT-PCR (
Table 4
| Mouse | Non-Human Primates | Rabbit | Wild boar | Cattle | |
|---|---|---|---|---|---|
| IL-1β | ( | ( | ( | ||
| IL-6 | ( | ( | ( | ( | |
| IL-10 | ( | ( | ( | ||
| IL-12 | ( | ||||
| IL-17A | ( | ||||
| IL-17 | ( | ( | |||
| IL-2 | ( | ||||
| IL-12p40 | ( | ||||
| IL-4 | ( | ||||
| IL-1α | ( | ( | |||
| IL-18 | (94) | ( | |||
| IL-8 | ( | ||||
| IL-12b | (148) | ||||
| IL-12p70 | ( | ||||
| IL-21 | ( |
Reported interleukins (IL) associated with innate responses against Mycobacterium tuberculosis complex (MTBC) differentiated by animal models.
Besides myeloid cells, TREM-1 is highly expressed in Vδ2 T cells of human patients with ATB and is involved in inflammation (153). In our review, increased TREM-1 signature-associated transcripts were associated with higher inflammation and disease severity in NHP at the time of diagnosis (90-180 d.p.i), similarly observed in human studies (
3.2.3.12 Eicosanoids and enzymes that participate in their synthesis
Eicosanoids are lipid mediators derived from arachidonic acid, produced by cyclooxygenases (COXs) and lipoxygenases (LOs), among other enzymes. These mediators include prostaglandins, resolvins, lipoxins, and leukotrienes (154–159). Eicosanoids have protective functions in innate and adaptive responses after Mtb infection (
3.2.4 Proteins exclusively present in insects
Despite being mentioned only by Asai et al., several insect proteins were described in a discovery-mass spectrometry-based approach (Table 5) (
Table 5
| Insect protein | Trend in infected larvae | Homologous proteins or those with similar functions in humans (or mammals) |
|---|---|---|
| Heat shock protein (HSP) | ↓ at 4 h.p.i | HSP is a conserved family of proteins (161) |
| Hemolin | ↑ at 4 h.p.i | Not found, but C-type lectins, Immunoglobulin superfamily, or Mannose-binding lectin (MBL) are suggested (162) |
| Gloverin | ↑ at 48 h.p.i | Not found but could be linked to defensins or LL-37 (162). |
| Yellow-d | ↑ at 48 h.p.i | Not found. |
| Insect metalloproteinase inhibitor (IMPIα) | ↑ at 48 h.p.i | Not found but could be linked to Tissue Inhibitors of Metalloproteinases (TIMPs) (163). |
| Peptidoglycan recognition protein | ↑ at 48 h.p.i | PGRP is a conserved family of proteins (164). |
| Prophenol oxidase activating enzyme3 | ↑ at 48 h.p.i | Not found. However, it has immunomodulatory functions analogous to the complement system (162, 165) |
| Putative defence protein Hdd11 | ↑ at 48 h.p.i | Not found. However, it could share functions with α- and β -defensins (162). |
| Cecropins D, A, C | ↑ at 48 h.p.i | Defensins, LL-37, Dermcidin (162) |
| Serpin-2, 3a, 4B, and 11. | ↑ at 48 h.p.i | Serpins are a conserved family of proteins (166) |
| Beta-1,3-glucan-binding protein (BGBP) | ↑ at 48 h.p.i | β-1,3 glucan (162) |
| 27KDa hemolymph | ↓ at 48 h.p.i | Not found. |
| Lysozyme-like protein 1 | ↓ at 48 h.p.i | Lysozyme (LYZ) is a conserved protein (162) |
| Scolexin | ↓ at 48 h.p.i | Not found. However, functional analogues could be C-type lectins and serine proteases (167). |
| Apolipophorins 1 and 2 (encoded by the same gene) | ↓ at 168 h.p.i | Apolipoprotein B (apoB) (168) |
Insect proteins found in BCG-infected Galleria mellonella hemolymph compared to uninfected larvae (
h.p.i, hours post infection.Symbol ↑ stand for increased and for symbol ↓ stand for decreased.
Additionally, the protein scolexin, involved in coagulation, was reduced at the same time point (
3.2.5 Other relevant molecules
3.2.5.1 Metabolites
This review explores the role of various metabolites that influence the early immune response to MTBC infection. Vitamin B5 has shown promise by reducing bacterial load, promoting macrophage maturation, and increasing pro-inflammatory cytokine levels (TNF-α, IFN-γ, IL-17) in mice as early as one-week postinfection (
Another metabolite examined is 5-OP-RU ((5-(2-oxopropylideneamino)-6-D-ribitylaminouracil), an intermediate in bacterial riboflavin biosynthesis, which has demonstrated contrasting effects in vitro and in vivo. In vitro, 5-OP-RU activates MAIT cells, but in vivo, it requires co-stimulation with the TLR2/6 agonist Pam2Cys to promote pulmonary MAIT cell expansion in mice (
3.2.5.2 Drugs as potential modulators of innate responses
We found several drug treatments with the potential for modulating the innate immune response and inhibiting Mtb or M. bovis growth, all of them evaluated in the mouse model. Biapenem and tubastatin A activated DCs and macrophages, reducing Mtb growth and suggesting new therapeutic avenues that stimulate the innate immune response (
Hussain et al. also reported that nilotinib induced both parkin and LC3-II proteins in the lung of M. bovis infected animals at 63 d.p.i. In a natural infection, M. bovis leads to the overexpression of the Abelson tyrosine kinase (Abl), that inhibits parkin, which is crucial to promote ubiquitin accumulation around the bacilli for its elimination (
Pharmacological inhibition of COX-2, administering Celecoxib shortly before and daily after infection, significantly reduced bacterial load in the lungs of infected mice (
Pretreatment with anti-TB drugs like INH and pyrazinamide (but not rifampicin) disrupted the mouse microbiota, leading to an increase in the Firmicutes phylum and reduced MHC-II expression in AM at five d.p.i, which worsened lung and extrapulmonary pathology (
4 Conclusions
Our review highlights a wide range of innate immune pathways activated during MTBC infections, specifically those caused by Mtb and M. bovis. Many of these pathways are highly conserved across mammals, and some, such as phagocytosis, oxidative stress responses, and antimicrobial peptide production, are also found in insects. Larvae of G. mellonella was proposed as a cost-effective and ethical model to study MTBC-host interactions relevant to human disease. The lack of adaptive immunity in insects (and other invertebrates), may offer valuable insights into “pure” innate immune responses. On the other hand, mice, though less susceptible to MTBC infections, are commonly used to study innate immune responses. The use of more susceptible strains and KO mouse mutants has led to discoveries of key immune mechanisms, such as trained immunity, the impact of metabolic co-morbidities (diabetes), and the early protection induced by specific soluble mediators (such as Cish, Parkin, Atg5, transcription factors like Bhlhe40, among others), eosinophils and receptors (CLECSF8).
Interestingly, the study of innate responses to MTBC also depends on the bacterial strain. For example, early protective factors against hypervirulent strains, like the Beijing strain, include IL-17 while a detrimental role was reported for the P2X7R receptor. Strains like HN878 lead to higher early recruitment of macrophages and PMN in rabbits, contributing to the formation of cavitary lesions.
The complexity of TB as a chronic disease makes it challenging to track time-dependent innate responses, especially as adaptive immune responses emerge after seven d.p.i. We must emphasize that these late “sustained” innate mediators were mainly evaluated after BCG vaccination and in the context of trained immunity. Articles explicitly describing trained immunity in mice and calves highlight the role of airway macrophages (IM and MdM) and neutrophils and the independence of NOD1 and 2 receptors and NK. The protective effect of many of the “sustained” innate responses driven by BCG vaccination in mammals and insects should be evaluated in the context of a later in vivo infection, in addition to ex-vivo experiments. Epigenetic changes associated with these memory-innate responses should be confirmed in vivo in different cell types using high-resolution methods to explore temporospatial histone, DNA, and RNA modifications (179).
One of the earliest innate responses observed occurs within 30 minutes of MTBC infection and involves neutrophils. Neutrophil activation emerged as one of the most frequently studied pathways, though it was often linked to excessive inflammation and disease severity. Interestingly, neutrophils were also found to have a protective role in early infection in BCG vaccinated mice. A key factor in this response was prg2 (Table 2), which is also involved in the eosinophil response. The protective role of eosinophils was further evaluated in mice and NHP.
Finally, recent research has expanded our understanding of the gut microbiota’s role in impairing innate immune responses towards MTBC and how the use of broad-spectrum antibiotics (pre-infection) can modulate these responses by altering gut microbiota composition. Additionally, the identification of specific innate pathways or mediators could help us to identify early or “sustained” responses associated with disease severity or protective responses. These biomarkers could be relevant in the evaluation of disease progression or immunization efficiency. Protective responses could be dynamic, as immunization could induce different responses depending on the age at which the vaccine is administered. One limitation of this review is its exclusive focus on in vivo studies, which excludes valuable findings from in vitro or organoid models. Due to the extent of this topic and the PICO question we established for the systematic review, we could not explore some of the mechanisms behind the responses measured in greater detail. Moreover, the role of sex differences in immune responses was not addressed, which represents a critical area for future research.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Author contributions
LN: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing. CM: Data curation, Formal analysis, Investigation, Methodology, Software, Writing – review & editing. KD: Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study used internal discretionary research funds provided to Dobos laboratory.
Acknowledgments
We would like to acknowledge the Colorado State University Libraries for their support during the collection of the reviewed articles.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1467016/full#supplementary-material
References
1
BespiatykhDBespyatykhJMokrousovIShitikovE. A comprehensive map of mycobacterium tuberculosis complex regions of difference. mSphere. (2021) 6. doi: 10.1128/mSphere.00535-21
2
ZhangHLiuMFanWSunSFanX. The impact of Mycobacterium tuberculosis complex in the environment on one health approach. Front Public Health. (2022) 10:994745. doi: 10.3389/fpubh.2022.994745
3
World Health Organization. Global Tuberculosis Report 2024. Geneva (2024).
4
DawsonKLBellAKawakamiRPColeyKYatesGCollinsDM. Transmission of Mycobacterium orygis (M. tuberculosis Complex Species) from a Tuberculosis Patient to a Dairy Cow in New Zealand. J Clin Microbiol. (2012) 50:3136–8. doi: 10.1128/JCM.01652-12
5
AdesokanHKAkinseyeVOStreicherEMVan HeldenPWarrenRMCadmusSI. Reverse zoonotic tuberculosis transmission from an emerging Uganda I strain between pastoralists and cattle in South-Eastern Nigeria. BMC Vet Res. (2019) 15:437. doi: 10.1186/s12917-019-2185-1
6
CarpenterSO’NeillLAJ. From periphery to center stage: 50 years of advancements in innate immunity. Cell. (2024) 187:2030–51. doi: 10.1016/j.cell.2024.03.036
7
SankarPMishraBB. Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis. Front Immunol. (2023) 14:1260859. doi: 10.3389/fimmu.2023.1260859
8
MarshallJSWarringtonRWatsonWKimHL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. (2018) 14:49. doi: 10.1186/s13223-018-0278-1
9
Ravesloot-ChávezMMVan DisEStanleySA. The innate immune response to mycobacterium tuberculosis infection. Annu Rev Immunol. (2021) 39:611–37. doi: 10.1146/annurev-immunol-093019-010426
10
SiaJKRengarajanJ. Immunology of mycobacterium tuberculosis infections. Microbiol Spectr. (2019) 7. doi: 10.1128/microbiolspec.GPP3-0022-2018
11
LoweDMRedfordPSWilkinsonRJO’GarraAMartineauAR. Neutrophils in tuberculosis: friend or foe? Trends Immunol. (2012) 33:14–25. doi: 10.1016/j.it.2011.10.003
12
ConnellyANHuijbregtsRPHPalHCKuznetsovaVDavisMDOngKLet al. Optimization of methods for the accurate characterization of whole blood neutrophils. Sci Rep. (2022) 12:3667. doi: 10.1038/s41598-022-07455-2
13
BlanterMGouwyMStruyfS. Studying neutrophil function in vitro: cell models and environmental factors. J Inflammation Res. (2021) 14:141–62. doi: 10.2147/JIR.S284941
14
KontsevayaICabibbeAMCirilloDMDiNardoARFrahmNGillespieSHet al. Update on the diagnosis of tuberculosis. Clin Microbiol Infection. (2024) 30:1115–22. doi: 10.1016/j.cmi.2023.07.014
15
PaiMBehrMADowdyDDhedaKDivangahiMBoehmeCCet al. Tuberculosis. Nat Rev Dis Primers. (2016) 2:16076. doi: 10.1038/nrdp.2016.76
16
CadenaAMFortuneSMFlynnJL. Heterogeneity in tuberculosis. Nat Rev Immunol. (2017) 17:691–702. doi: 10.1038/nri.2017.69
17
DrainPKBajemaKLDowdyDDhedaKNaidooKSchumacherSGet al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. (2018) 31. doi: 10.1128/CMR.00021-18
18
TiemersmaEWvan der WerfMJBorgdorffMWWilliamsBGNagelkerkeNJD. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PloS One. (2011) 6:e17601. doi: 10.1371/journal.pone.0017601
19
JalbertELiuCMaveVLangNKagalAValviCet al. Comparative immune responses to Mycobacterium tuberculosis in people with latent infection or sterilizing protection. iScience. (2023) 26:107425. doi: 10.1016/j.isci.2023.107425
20
ZengGZhangGChenX. Th1 cytokines, true functional signatures for protective immunity against TB? Cell Mol Immunol. (2018) 15:206–15. doi: 10.1038/cmi.2017.113
21
SherAFlynnJL. Sterilizing immunity: New opportunities for rational TB vaccine design. J Exp Med. (2021) 218. doi: 10.1084/jem.20210454
22
HooijmansCRde VriesRBMRitskes-HoitingaMRoversMMLeeflangMMIntHoutJet al. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. PloS One. (2018) 13:e0187271. doi: 10.1371/journal.pone.0187271
23
PageMJMcKenzieJEBossuytPMBoutronIHoffmannTCMulrowCDet al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) n71. doi: 10.1136/bmj.n71
24
DivangahiMAabyPKhaderSABarreiroLBBekkeringSChavakisTet al. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. (2021) 22:2–6. doi: 10.1038/s41590-020-00845-6
25
SherwoodERBurelbachKRMcBrideMAStothersCLOwenAMHernandezAet al. Innate immune memory and the host response to infection. J Immunol. (2022) 208:785–92. doi: 10.4049/jimmunol.2101058
26
ChristABekkeringSLatzERiksenNP. Long-term activation of the innate immune system in atherosclerosis. Semin Immunol. (2016) 28:384–93. doi: 10.1016/j.smim.2016.04.004
27
AronovaATosatoFNaserNAsareY. Innate immune pathways in atherosclerosis—From signaling to long-term epigenetic reprogramming. Cells. (2023) 12:2359. doi: 10.3390/cells12192359
28
BoassoAShearerGM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol. (2008) 126:235–42. doi: 10.1016/j.clim.2007.08.015
29
BickettTEMcLeanJCreissenEIzzoLHaganCIzzoAJet al. Characterizing the BCG induced macrophage and neutrophil mechanisms for defense against mycobacterium tuberculosis. Front Immunol. (2020) 11:1202. doi: 10.3389/fimmu.2020.01202
30
D’AgostinoMRLaiRAfkhamiSKheraAYaoYVaseghi-ShanjaniMet al. Airway Macrophages Mediate Mucosal Vaccine–Induced Trained Innate Immunity against Mycobacterium tuberculosis in Early Stages of Infection. J Immunol. (2020) 205:2750–62. doi: 10.4049/jimmunol.2000532
31
Guerra-MaupomeMVangDXMcGillJL. Aerosol vaccination with Bacille Calmette-Guerin induces a trained innate immune phenotype in calves. PloS One. (2019) 14. doi: 10.1371/journal.pone.0212751
32
SteiglerPDanielsNJMcCullochTRRyderBMSandfordSKKirmanJR. BCG vaccination drives accumulation and effector function of innate lymphoid cells in murine lungs. Immunol Cell Biol. (2018) 96:379–89. doi: 10.1111/imcb.12007
33
SarfasCWhiteADSibleyLMorrisonALGullickJLawrenceSet al. Characterization of the infant immune system and the influence and immunogenicity of BCG vaccination in infant and adult rhesus macaques. Front Immunol. (2021) 12:754589. doi: 10.3389/fimmu.2021.754589
34
NeteaMGQuintinJvan der MeerJWM. Trained immunity: A memory for innate host defense. Cell Host Microbe. (2011) 9:355–61. doi: 10.1016/j.chom.2011.04.006
35
KaufmannESanzJDunnJLKhanNMendonçaLEPacisAet al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell. (2018) 172:176–190.e19. doi: 10.1016/j.cell.2017.12.031
36
KhanNDowneyJSanzJKaufmannEBlankenhausBPacisAet al. M. tuberculosis reprograms hematopoietic stem cells to limit myelopoiesis and impair trained immunity. Cell. (2020) 183:752–770.e22. doi: 10.1016/j.cell.2020.09.062
37
Beltrán-BeckBde la FuenteJGarridoJMAranazASevillaIVillarMet al. Oral vaccination with heat inactivated Mycobacterium bovis activates the complement system to protect against tuberculosis. PloS One. (2014) 9. doi: 10.1371/journal.pone.0098048
38
StinearTPSeemannTHarrisonPFJenkinGADaviesJKJohnsonPDRet al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res. (2008) 18:729–41. doi: 10.1101/gr.075069.107
39
de OliveiraFMProcopioVOMenezes G deLda SilvaRAKipnisAJunqueira-KipnisAP. Mycobacterium bovis pknG R242P mutation results in structural changes with enhanced virulence in the mouse model of infection. Microorganisms. (2022) 10. doi: 10.3390/MICROORGANISMS10040673
40
CarowBGaoYTeránGYangXODongCYoshimuraAet al. CISH controls bacterial burden early after infection with Mycobacterium tuberculosis in mice. Tuberculosis. (2017) 107:175–80. doi: 10.1016/j.tube.2017.09.007
41
WilsonGJMarakalalaMJHovingJCVan LaarhovenADrummondRAKerscherBet al. The C-type lectin receptor CLECSF8/CLEC4D is a key component of anti-mycobacterial immunity. Cell Host Microbe. (2015) 17:252–9. doi: 10.1016/j.chom.2015.01.004
42
FranciscoNMHsuNJKeetonRRandallPSebeshoBAllieNet al. TNF-dependent regulation and activation of innate immune cells are essential for host protection against cerebral tuberculosis. J Neuroinflamm. (2015) 12. doi: 10.1186/s12974-015-0345-1
43
PalLNandaniRKumarPSwamiBRoyG. Macrophages are the key players in promoting hyper-inflammatory response in a mouse model of TB-IRIS. Front Immunol. (2021) 12:775177. doi: 10.3389/fimmu.2021.775177
44
GuptaSWingleeKGalloRBishaiWR. Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis. J Pathol. (2017) 242:52–61. doi: 10.1002/path.4878
45
HuynhJPLinCCKimmeyJMJarjourNNSchwarzkopfEABradstreetTRet al. Bhlhe40 is an essential repressor of IL-10 during Mycobacterium tuberculosis infection. J Exp Med. (2018) 215:1823–38. doi: 10.1084/jem.20171704
46
HuangYMatsumuraYHatanoSNoguchiNMurakamiTIwakuraYet al. IL-21 inhibits IL-17A-producing γδ T-cell response after infection with Bacillus Calmette-Guérin via induction of apoptosis. Innate Immun. (2016) 22:588–97. doi: 10.1177/1753425916664125
47
AmaralEPRibeiroSCMLanesVRAlmeidaFMde AndradeMRMBomfimCCBet al. Pulmonary infection with hypervirulent mycobacteria reveals a crucial role for the P2X7 receptor in aggressive forms of tuberculosis. PloS Pathog. (2014) 10. doi: 10.1371/journal.ppat.1004188
48
GuptaTSarrDFantoneKAshtiwiNMSakamotoKQuinnFDet al. Dual oxidase 1 is dispensable during Mycobacterium tuberculosis infection in mice. Front Immunol. (2023) 14:1044703. doi: 10.3389/fimmu.2023.1044703
49
VogelzangALozzaLReeceSTPerdomoCZedlerUHahnkeKet al. Neonatal Fc receptor regulation of lung immunoglobulin and CD103+ dendritic cells confers transient susceptibility to tuberculosis. Infect Immun. (2016) 84:2914–21. doi: 10.1128/IAI.00533-16
50
DasRKooMSKimBHJacobSTSubbianSYaoJet al. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc Natl Acad Sci U.S.A. (2013) 110. doi: 10.1073/pnas.1301128110
51
LeeJBrehmMAGreinerDShultzLDKornfeldH. Engrafted human cells generate adaptive immune responses to Mycobacterium bovis BCG infection in humanized mice. BMC Immunol (2013) 14:53. doi: 10.1186/1471-2172-14-53
52
BohrerACCastroEHuZQueirozATLTochenyCEAssmannMet al. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J Exp Med. (2021) 218. doi: 10.1084/jem.20210469
53
KimmeyJMHuynhJPWeissLAParkSKambalADebnathJet al. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nat. (2015) 528:565–9. doi: 10.1038/nature16451
54
Moreira-TeixeiraLStimpsonPJStavropoulosEHadebeSChakravartyPIoannouMet al. Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis. Nat Commun. (2020) 11. doi: 10.1038/s41467-020-19412-6
55
SubbianSBandyopadhyayNTsenovaLO’BrienPKhetaniVKushnerNLet al. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Communication Signaling. (2013) 11. doi: 10.1186/1478-811X-11-60
56
Henao-TamayoMObregón-HenaoACreissenEShanleyCOrmeIOrdwayDJ. Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis. Clin Vaccine Immunol. (2015) 22:91–8. doi: 10.1128/CVI.00466-14
57
WilliamsAOrmeIM. Animal models of tuberculosis: an overview. Microbiol Spectr. (2016) 4. doi: 10.1128/microbiolspec.TBTB2-0004-2015
58
LiHLiH. “Animal models of tuberculosis.,”. In: Vaccines for neglected pathogens: strategies, achievements and challenges. Springer International Publishing, Cham (2023). p. 139–70. doi: 10.1007/978-3-031-24355-4_7
59
DharmadhikariASNardellEA. What animal models teach humans about tuberculosis. Am J Respir Cell Mol Biol. (2008) 39:503–8. doi: 10.1165/rcmb.2008-0154TR
60
SinghAGuptaU. Animal models of tuberculosis: Lesson learnt. Indian J Med Res. (2018) 147:456. doi: 10.4103/ijmr.IJMR_554_18
61
PlumleeCRDuffyFJGernBHDelahayeJLCohenSBStoltzfusCRet al. Ultra-low dose aerosol infection of mice with mycobacterium tuberculosis more closely models human tuberculosis. Cell Host Microbe. (2021) 29:68–82.e5. doi: 10.1016/j.chom.2020.10.003
62
SoldevillaPVilaplanaCCardonaP-J. Mouse models for mycobacterium tuberculosis pathogenesis: show and do not tell. Pathogens. (2022) 12:49. doi: 10.3390/pathogens12010049
63
BehrouziAAlimohammadiMNafariAHYousefiMHRiazi RadFVaziriFet al. The role of host miRNAs on Mycobacterium tuberculosis. ExRNA. (2019) 1:40. doi: 10.1186/s41544-019-0040-y
64
ChengYSchoreyJS. Mycobacterium tuberculosis-induced IFN-β production requires cytosolic DNA and RNA sensing pathways. J Exp Med. (2018) 215:2919–35. doi: 10.1084/jem.20180508
65
CooperAM. doi: 10.1101/cshperspect.a018556
66
LaddyDJBonaviaAHanekomWAKaushalDWilliamsARoedererMet al. Toward tuberculosis vaccine development: recommendations for nonhuman primate study design. Infect Immun. (2018) 86. doi: 10.1128/IAI.00776-17
67
OrmeIM. The mouse as a useful model of tuberculosis. Tuberculosis. (2003) 83:112–5. doi: 10.1016/S1472-9792(02)00069-0
68
BoutéMCarrerasFRossignolCDozEWinterNEpardaudM. The C3HeB/FeJ mouse model recapitulates the hallmark of bovine tuberculosis lung lesions following Mycobacterium bovis aerogenous infection. Vet Res. (2017) 48:73. doi: 10.1186/s13567-017-0477-7
69
DriverERRyanGJHoffDRIrwinSMBasarabaRJKramnikIet al. Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother. (2012) 56:3181–95. doi: 10.1128/AAC.00217-12
70
CoppolaMJurionFvan den EedenSJFTimaHGFrankenKLMCGelukAet al. In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. NPJ Vaccines. (2021) 6:81. doi: 10.1038/s41541-021-00343-2
71
AlimMASikderSSathkumaraHKupzARushCMGovanBLet al. Dysregulation of key cytokines may contribute to increased susceptibility of diabetic mice to Mycobacterium bovis BCG infection. Tuberculosis. (2019) 115:113–20. doi: 10.1016/j.tube.2019.02.005
72
AlimMAKupzASikderSRushCGovanBKetheesanN. Increased susceptibility to Mycobacterium tuberculosis infection in a diet-induced murine model of type 2 diabetes. Microbes Infect. (2020) 22:303–11. doi: 10.1016/j.micinf.2020.03.004
73
BucsanANRoutNForemanTWKhaderSARengarajanJKaushalD. Mucosal-activated invariant T cells do not exhibit significant lung recruitment and proliferation profiles in macaques in response to infection with Mycobacterium tuberculosis CDC1551. Tuberculosis. (2019) 116:S11–8. doi: 10.1016/j.tube.2019.04.006
74
KolloliASinghPMarcela RodriguezGSubbianS. Effect of iron supplementation on the outcome of non-progressive pulmonary Mycobacterium tuberculosis infection. J Clin Med. (2019) 8. doi: 10.3390/jcm8081155
75
WangXTangXZhouZHuangQ. Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice. Pathog Dis. (2018) 76. doi: 10.1093/femspd/fty064
76
NegiSPahariSBashirHAgrewalaJN. Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice. Eur J Immunol. (2020) 50:1976–87. doi: 10.1002/eji.202048556
77
UmemuraMOkamoto-YoshidaYYahagiATouyamaSNakaeSIwakuraYet al. Involvement of IL-17A-producing TCR γδ T cells in late protective immunity against pulmonary mycobacterium tuberculosis infection. Immun Inflammation Dis. (2016) 4:401–12. doi: 10.1002/iid3.121
78
ChenYXiaoJNLiYXiaoYJXiongYQLiuYet al. Mycobacterial lipoprotein Z triggers efficient innate and adaptive immunity for protection against Mycobacterium tuberculosis infection. Front Immunol. (2019) 10:3190. doi: 10.3389/fimmu.2018.03190
79
Ramos-EspinosaOHernández-BazánSFrancisco-CruzAMata-EspinosaDBarrios-PayánJMarquina-CastilloBet al. Gene therapy based in antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis. Pathog Dis. (2016) 74. doi: 10.1093/femspd/ftw075
80
KroesenVMRodríguez-MartínezPGarcíaERosalesYDíazJMartín-CéspedesMet al. A beneficial effect of low-dose aspirin in a murine model of active tuberculosis. Front Immunol. (2018) 9:798. doi: 10.3389/fimmu.2018.00798
81
KinsellaRLKimmeyJMSmirnovAWoodsonRGaggioliMRChavezSMet al. Autophagy prevents early proinflammatory responses and neutrophil recruitment during Mycobacterium tuberculosis infection without affecting pathogen burden in macrophages. PloS Biol. (2023) 21:e3002159. doi: 10.1371/journal.pbio.3002159
82
MarzoEVilaplanaCTapiaGDiazJGarciaVCardonaP-J. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis. (2014) 94:55–64. doi: 10.1016/j.tube.2013.09.004
83
HeWHuSDuXWenQZhongX-PZhouXet al. Vitamin B5 Reduces Bacterial Growth via Regulating Innate Immunity and Adaptive Immunity in Mice Infected with Mycobacterium tuberculosis. Front Immunol. (2018) 9:365. doi: 10.3389/fimmu.2018.00365
84
NadellaVSharmaLKumarPGuptaPGuptaUDTripathiSet al. Sphingosine-1-phosphate (S-1P) promotes differentiation of naive macrophages and enhances protective immunity against mycobacterium tuberculosis. Front Immunol. (2020) 10:3085. doi: 10.3389/fimmu.2019.03085
85
SinghBSinghDKGanatraSREscobedoRAKhaderSSchlesingerLSet al. Myeloid-Derived Suppressor Cells Mediate T Cell Dysfunction in Nonhuman Primate TB Granulomas. mBio (2021) 12:e03189–21. doi: 10.1128/mbio.03189-21
86
Mayer-BarberKDAndradeBBOlandSDAmaralEPBarberDLGonzalesJet al. Host-directed therapy of tuberculosis based on interleukin-1 and type i interferon crosstalk. Nature. (2014) 511:99–103. doi: 10.1038/nature13489
87
YadavBMaloniaSKMajumdarSSGuptaPWadhwaNBadhwarAet al. Constitutive expression of SMAR1 confers susceptibility to mycobacterium tuberculosis infection in a transgenic mouse model. Indian J Med Res. (2015) 142:732–41. doi: 10.4103/0971-5916.174566
88
WangYYangCHeYZhanXXuL. Ipr1 modified BCG as a novel vaccine induces stronger immunity than BCG against tuberculosis infection in mice. Mol Med Rep. (2016) 14:1756–64. doi: 10.3892/mmr.2016.5447
89
VorkasCKLevyOSkularMLiKAubéJGlickmanMS. Efficient 5-OP-RU-induced enrichment of mucosa-associated invariant T cells in the murine lung does not enhance control of aerosol mycobacterium tuberculosis infection. Infect Immun. (2020) 89. doi: 10.1128/IAI.00524-20
90
Filio-RodríguezGEstrada-GarcíaIArce-ParedesPMoreno-AltamiranoMMIslas-TrujilloSPonce-RegaladoMDet al. In vivo induction of neutrophil extracellular traps by Mycobacterium tuberculosis in a Guinea pig model. Innate Immun. (2017) 23:625–37. doi: 10.1177/1753425917732406
91
AbnavePMottolaGGimenezGBoucheritNTrouplinVTorreCet al. Screening in planarians identifies MORN2 as a key component in LC3-associated phagocytosis and resistance to bacterial infection. Cell Host Microbe. (2014) 16:338–50. doi: 10.1016/j.chom.2014.08.002
92
HussainTZhaoDShahSZASabirNWangJLiaoYet al. Nilotinib: A tyrosine kinase inhibitor mediates resistance to intracellular mycobacterium via regulating autophagy. Cells. (2019) 8:506. doi: 10.3390/cells8050506
93
HansenSGZakDEXuGFordJCMarshallEEMalouliDet al. Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nat Med. (2018) 24:130–43. doi: 10.1038/nm.4473
94
KupzAZedlerUStäberMPerdomoCDorhoiABroschRet al. ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo. J Clin Invest. (2016) 126:2109–22. doi: 10.1172/JCI84978
95
LouJWangYZhangZQiuW. MiR-20b inhibits mycobacterium tuberculosis induced inflammation in the lung of mice through targeting NLRP3. Exp Cell Res. (2017) 358:120–8. doi: 10.1016/j.yexcr.2017.06.007
96
Montoya-RosalesAProvvediRTorres-JuarezFEnciso-MorenoJAHernandez-PandoRManganelliRet al. lysX gene is differentially expressed among Mycobacterium tuberculosis strains with different levels of virulence. Tuberculosis. (2017) 106:106–17. doi: 10.1016/j.tube.2017.07.005
97
Ramos-EspinosaOMata-EspinosaDFrancisco-CruzALópez-TorresMOHernández-BazánSBarrios-PayánJet al. Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis. J Leukoc Biol. (2021) 110:951–63. doi: 10.1002/JLB.4MA0920-627R
98
LópezVVillarMQueirósJVicenteJMateos-HernándezLDíez-DelgadoIet al. Comparative proteomics identifies host immune system proteins affected by infection with mycobacterium bovis. PloS Negl Trop Dis. (2016) 10. doi: 10.1371/journal.pntd.0004541
99
AsaiMSheehanGLiYRobertsonBDKavanaghKLangfordPRet al. Innate Immune Responses of Galleria mellonella to Mycobacterium bovis BCG Challenge Identified Using Proteomic and Molecular Approaches. Front Cell Infect Microbiol. (2021) 11:619981. doi: 10.3389/fcimb.2021.619981
100
KhanNMendoncaLDhariwalAFontesGMenziesDXiaJet al. Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. Mucosal Immunol. (2019) 12:772–83. doi: 10.1038/s41385-019-0147-3
101
AqdasMMauryaSKPahariSSinghSKhanNSethiKet al. Immunotherapeutic role of NOD-2 and TLR-4 signaling as an adjunct to antituberculosis chemotherapy. ACS Infect Dis. (2021) 7:2999–3008. doi: 10.1021/acsinfecdis.1c00136
102
GopalakrishnanADietzoldJSalgameP. Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9. Cell Immunol. (2016) 302:11–8. doi: 10.1016/j.cellimm.2015.12.009
103
BerodLStüvePSwallowMArnold-SchraufCKruseFGentiliniMVet al. MyD88 signalling in myeloid cells is sufficient to prevent chronic mycobacterial infection. Eur J Immunol. (2014) 44:1399–409. doi: 10.1002/eji.201344039
104
JavedSMarsayLWarehamALewandowskiKSWilliamsADennisMJet al. Temporal expression of peripheral blood leukocyte biomarkers in a Macaca fascicularis infection model of tuberculosis; comparison with human datasets and analysis with parametric/non-parametric tools for improved diagnostic biomarker identification. PloS One. (2016) 11. doi: 10.1371/journal.pone.0154320
105
SorgiCASoaresEMRosadaRSBitencourtCSZoccalKFPereiraPATet al. Eicosanoid pathway on host resistance and inflammation during Mycobacterium tuberculosis infection is comprised by LTB4 reduction but not PGE2 increment. Biochim Biophys Acta Mol Basis Dis. (2020) 1866. doi: 10.1016/j.bbadis.2019.165574
106
ChoiH-GChoiSBackYWParkH-SBaeHSChoiCHet al. Mycobacterium tuberculosis Rv2882c Protein Induces Activation of Macrophages through TLR4 and Exhibits Vaccine Potential. PloS One. (2016) 11:e0164458. doi: 10.1371/journal.pone.0164458
107
DonathMYShoelsonSE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. (2011) 11:98–107. doi: 10.1038/nri2925
108
NymanTALoreyMBCyprykWMatikainenS. Mass spectrometry-based proteomic exploration of the human immune system: focus on the inflammasome, global protein secretion, and T cells. Expert Rev Proteomics. (2017) 14:395–407. doi: 10.1080/14789450.2017.1319768
109
BennikeTB. Advances in proteomics: characterization of the innate immune system after birth and during inflammation. Front Immunol. (2023) 14:1254948. doi: 10.3389/fimmu.2023.1254948
110
SpitsHCupedoT. Innate lymphoid cells: Emerging insights in development, lineage relationships, and function. Annu Rev Immunol. (2012) 30:647–75. doi: 10.1146/annurev-immunol-020711-075053
111
GideonHPSkinnerJABaldwinNFlynnJLLinPL. Early whole blood transcriptional signatures are associated with severity of lung inflammation in cynomolgus macaques with mycobacterium tuberculosis infection. J Immunol. (2016) 197:4817–28. doi: 10.4049/jimmunol.1601138
112
FlynnJLGideonHPMattilaJTLinPL. Immunology studies in non-human primate models of tuberculosis. Immunol Rev. (2015) 264:60–73. doi: 10.1111/imr.12258
113
DijkmanKVervenneRAWSombroekCCBootCHofmanSOvan MeijgaardenKEet al. Disparate tuberculosis disease development in macaque species is associated with innate immunity. Front Immunol. (2019) 10:2479. doi: 10.3389/fimmu.2019.02479
114
EdmansMDConnelleyTKJayaramanSVrettouCVordermeierMMakJYWet al. Identification and phenotype of MAIT cells in cattle and their response to bacterial infections. Front Immunol. (2021) 12:627173. doi: 10.3389/fimmu.2021.627173
115
KleinnijenhuisJQuintinJPreijersFJoostenLABIfrimDCSaeedSet al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci. (2012) 109:17537–42. doi: 10.1073/pnas.1202870109
116
KleinnijenhuisJQuintinJPreijersFJoostenLABJacobsCXavierRJet al. BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin Immunol. (2014) 155:213–9. doi: 10.1016/j.clim.2014.10.005
117
ClarkSHallYWilliamsA. Animal models of tuberculosis: Guinea pigs. Cold Spring Harb Perspect Med. (2015) 5:a018572–a018572. doi: 10.1101/cshperspect.a018572
118
LiYSpiropoulosJCooleyWKharaJSGladstoneCAAsaiMet al. Galleria mellonella-a novel infection model for the mycobacterium tuberculosis complex. Virulence. (2018) 9:1126–37. doi: 10.1080/21505594.2018.1491255
119
AsaiMLiYSpiropoulosJCooleyWEverestDJKendallSLet al. Galleria mellonella as an infection model for the virulent Mycobacterium tuberculosis H37Rv. Virulence. (2022) 13:1543–57. doi: 10.1080/21505594.2022.2119657
120
PrescottMJLidsterK. Improving quality of science through better animal welfare: the NC3Rs strategy. Lab Anim (NY). (2017) 46:152–6. doi: 10.1038/laban.1217
121
KlocMHalasaMKubiakJZGhobrialRM. Invertebrate immunity, natural transplantation immunity, somatic and germ cell parasitism, and transposon defense. Int J Mol Sci. (2024) 25:1072. doi: 10.3390/ijms25021072
122
Smith DFQCasadevallA. Fungal immunity and pathogenesis in mammals versus the invertebrate model organism. Galleria mellonella. Pathog Dis. (2021) 79. doi: 10.1093/femspd/ftab013
123
PerveenNMuhammadKBinMSZaheerTMunawarNGajicBet al. Host-pathogen interaction in arthropod vectors: Lessons from viral infections. Front Immunol. (2023) 14:1061899. doi: 10.3389/fimmu.2023.1061899
124
BaxterRHGContetAKruegerK. Arthropod innate immune systems and vector-borne diseases. Biochemistry. (2017) 56:907–18. doi: 10.1021/acs.biochem.6b00870
125
de JongAWvan VeldhuizenDGrootATHagenF. Standardized methods to rear high-quality Galleria mellonella larvae for the study of fungal pathogens. Entomol Exp Appl. (2022) 170:1073–80. doi: 10.1111/eea.13237
126
SeniorNJTitballRW. Isolation and primary culture of Galleria mellonella hemocytes for infection studies. F1000Res. (2021) 9:1392. doi: 10.12688/f1000research.27504.2
127
ChoYChoS. Hemocyte-hemocyte adhesion by granulocytes is associated with cellular immunity in the cricket, Gryllus bimaculatus. Sci Rep. (2019) 9:18066. doi: 10.1038/s41598-019-54484-5
128
GalloriniMMarinacciBPellegriniBCataldiADindoMLCarradoriSet al. Immunophenotyping of hemocytes from infected Galleria mellonella larvae as an innovative tool for immune profiling, infection studies and drug screening. Sci Rep. (2024) 14:759. doi: 10.1038/s41598-024-51316-z
129
WrońskaAKKaczmarekASobichJGrzelakSBoguśMI. Intracellular cytokine detection based on flow cytometry in hemocytes from Galleria mellonella larvae: A new protocol. PloS One. (2022) 17:e0274120. doi: 10.1371/journal.pone.0274120
130
HammoudiNTorreCGhigoEDrancourtM. Temperature affects the biology of Schmidtea mediterranea. Sci Rep. (2018) 8. doi: 10.1038/s41598-018-33355-5
131
WuYWuMMingSZhanXHuSLiXet al. TREM-2 promotes Th1 responses by interacting with the CD3ζ-ZAP70 complex following Mycobacterium tuberculosis infection. J Clin Invest. (2021) 131. doi: 10.1172/JCI137407
132
YouKGuHYuanZXuX. Tumor necrosis factor alpha signaling and organogenesis. Front Cell Dev Biol. (2021) 9:727075. doi: 10.3389/fcell.2021.727075
133
SchoreyJSSchlesingerLS. Innate immune responses to tuberculosis. Microbiol Spectr. (2016) 4. doi: 10.1128/microbiolspec.tbtb2-0010-2016
134
HeCLuoHCoelhoALiuMLiQXuJet al. NCF4 dependent intracellular reactive oxygen species regulate plasma cell formation. Redox Biol. (2022) 56:102422. doi: 10.1016/j.redox.2022.102422
135
ScheuermannLPeiGDomaszewskaTZylaJOberbeck-MüllerDBandermannSet al. Platelets restrict the oxidative burst in phagocytes and facilitate primary progressive tuberculosis. Am J Respir Crit Care Med. (2020) 202:730–44. doi: 10.1164/rccm.201910-2063OC
136
MeierSSeddonJAMaasdorpEKleynhansLdu PlessisNLoxtonAGet al. Neutrophil degranulation, NETosis and platelet degranulation pathway genes are co-induced in whole blood up to six months before tuberculosis diagnosis. PloS One. (2022) 17:e0278295. doi: 10.1371/journal.pone.0278295
137
KathamuthuGRKumarNPMoideenKNairDBanurekhaVVSridharRet al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases are potential biomarkers of pulmonary and extra-pulmonary tuberculosis. Front Immunol. (2020) 11:419. doi: 10.3389/fimmu.2020.00419
138
BrozPDixitVM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. (2016) 16:407–20. doi: 10.1038/nri.2016.58
139
MaJZhaoSGaoXWangRLiuJZhouXet al. The Roles of Inflammasomes in Host Defense against Mycobacterium tuberculosis. Pathogens. (2021) 10:120. doi: 10.3390/pathogens10020120
140
ChenSSaeedAFUHLiuQJiangQXuHXiaoGGet al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. (2023) 8:207. doi: 10.1038/s41392-023-01452-1
141
GaoJLiangYWangL. Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol. (2022) 13:888713. doi: 10.3389/fimmu.2022.888713
142
StrizovaZBenesovaIBartoliniRNovysedlakRCecrdlovaEFoleyLKet al. M1/M2 macrophages and their overlaps – myth or reality? Clin Sci. (2023) 137:1067–93. doi: 10.1042/CS20220531
143
ZhengXFHongYXFengGJZhangGFRogersHLewisMAOet al. Lipopolysaccharide-induced M2 to M1 macrophage transformation for IL-12p70 production is blocked by candida albicans mediated up-regulation of EBI3 expression. PloS One. (2013) 8. doi: 10.1371/journal.pone.0063967
144
BahAVergneI. Macrophage autophagy and bacterial infections. Front Immunol. (2017) 8:1483. doi: 10.3389/fimmu.2017.01483
145
TanidaIUenoTKominamiE. LC3 and Autophagy. Methods Mol Biol. (2008) 445:77–88. doi: 10.1007/978-1-59745-157-4_4
146
NegiSPahariSBashirHAgrewalaJN. Gut microbiota regulates mincle mediated activation of lung dendritic cells to protect against mycobacterium tuberculosis. Front Immunol. (2019) 10:1142. doi: 10.3389/fimmu.2019.01142
147
GopalRMoninLSlightSUcheUBlanchardEA. Fallert JuneckoBet al. Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection. PloS Pathog. (2014) 10. doi: 10.1371/journal.ppat.1004099
148
WangJGePQiangLTianFZhaoDChaiQet al. The mycobacterial phosphatase PtpA regulates the expression of host genes and promotes cell proliferation. Nat Commun. (2017) 8. doi: 10.1038/s41467-017-00279-z
149
GengenbacherMVogelzangASchuererSLazarDKaiserPKaufmannSHE. Dietary pyridoxine controls efficacy of vitamin b6-auxotrophic tuberculosis vaccine bacillus calmette-Guérin ΔureC::Hly Δpdx1 in Mice. mBio. (2014) 5. doi: 10.1128/mBio.01262-14
150
NemethJOlsonGSRothchildACJahnANMaiDDuffyFJet al. Contained Mycobacterium tuberculosis infection induces concomitant and heterologous protection. PloS Pathog. (2020) 16:e1008655. doi: 10.1371/journal.ppat.1008655
151
MartinotAJBlassEYuJAidMMahrokhianSHCohenSBet al. Protective efficacy of an attenuated Mtb ΔLprG vaccine in mice. PloS Pathog. (2020) 16:e1009096. doi: 10.1371/journal.ppat.1009096
152
Esparza-GonzalezSCTroyARIzzoAA. Comparative analysis of Bacillus subtilis spores and monophosphoryl lipid A as adjuvants of protein-based Mycobacterium tuberculosis-based vaccines: Partial requirement for interleukin-17A for induction of protective immunity. Clin Vaccine Immunol. (2014) 21:501–8. doi: 10.1128/CVI.00622-13
153
HoogendijkAJBlokDCGarcia LaordenMIKagerLMLedeIORahmanWet al. Soluble and cell-associated triggering receptor expressed on myeloid cells-1 and -2 in patients with pulmonary tuberculosis. J Infection. (2015) 71:706–9. doi: 10.1016/j.jinf.2015.09.002
154
DennisEANorrisPC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. (2015) 15:511–23. doi: 10.1038/nri3859
155
DivangahiMDesjardinsDNunes-AlvesCRemoldHGBeharSM. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol. (2010) 11:751–8. doi: 10.1038/ni.1904
156
KaushalD. Eicosanoids, prostaglandins, and the progression of tuberculosis. J Infect Dis. (2012) 206:1803–5. doi: 10.1093/infdis/jis611
157
MorteauO. Prostaglandins and inflammation: the cyclooxygenase controversy. Inflammation. Dordrecht: Springer Netherlands (2001). p. 67–81. doi: 10.1007/978-94-015-9702-9_6
158
HariziHCorcuffJ-BGualdeN. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med. (2008) 14:461–9. doi: 10.1016/j.molmed.2008.08.005
159
KohliPLevyBD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol. (2009) 158:960–71. doi: 10.1111/j.1476-5381.2009.00290.x
160
NoreKGJørgensenMJDyrhol-RiiseAMJenumSTonbyK. Elevated levels of anti-inflammatory eicosanoids and monocyte heterogeneity in mycobacterium tuberculosis infection and disease. Front Immunol. (2020) 11:579849. doi: 10.3389/fimmu.2020.579849
161
SchlesingerMJ. Heat shock proteins. J Biol Chem. (1990) 265:12111–4. doi: 10.1016/S0021-9258(19)38314-0
162
SheehanGGarveyACrokeMKavanaghK. Innate humoral immune defences in mammals and insects: The same, with differences ? Virulence. (2018) 9:1625–39. doi: 10.1080/21505594.2018.1526531
163
BrewKDinakarpandianDNagaseH. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (BBA) - Protein Structure Mol Enzymology. (2000) 1477:267–83. doi: 10.1016/S0167-4838(99)00279-4
164
KangDLiuGLundströmAGeliusESteinerH. A peptidoglycan recognition protein in innate immunity conserved from insects to humans. Proc Natl Acad Sci. (1998) 95:10078–82. doi: 10.1073/pnas.95.17.10078
165
CereniusLSöderhällK. Immune properties of invertebrate phenoloxidases. Dev Comp Immunol. (2021) 122:104098. doi: 10.1016/j.dci.2021.104098
166
IrvingJA. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. (2000) 10:1845–64. doi: 10.1101/gr.GR-1478R
167
FinnertyCMGranadosRRKarplusPA. The insect immune protein scolexin is a novel serine proteinase homolog. Protein Sci. (1999) 8:242–8. doi: 10.1110/ps.8.1.242
168
ZhaoYLiuWZhaoXYuZGuoHYangYet al. Apolipophorin-II/I contributes to cuticular hydrocarbon transport and cuticle barrier construction in locusta migratoria. Front Physiol. (2020) 11:790. doi: 10.3389/fphys.2020.00790
169
SpenceMAMortimerMDBuckleAMMinhBQJacksonCJ. A comprehensive phylogenetic analysis of the serpin superfamily. Mol Biol Evol. (2021) 38:2915–29. doi: 10.1093/molbev/msab081
170
MeekinsDAKanostMRMichelK. Serpins in arthropod biology. Semin Cell Dev Biol. (2017) 62:105–19. doi: 10.1016/j.semcdb.2016.09.001
171
ReeceSTLoddenkemperCAskewDJZedlerUSchommer-LeitnerSSteinMet al. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest. (2010) 120:3365–76. doi: 10.1172/JCI42796
172
KolbeKVeletiSKReilingNLindhorstTK. Lectins of Mycobacterium tuberculosis – rarely studied proteins. Beilstein J Organic Chem. (2019) 15:1–15. doi: 10.3762/bjoc.15.1
173
SheehanGClarkeGKavanaghK. Characterisation of the cellular and proteomic response of Galleria mellonella larvae to the development of invasive aspergillosis. BMC Microbiol. (2018) 18:63. doi: 10.1186/s12866-018-1208-6
174
VegliaFSansevieroEGabrilovichDI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. (2021) 21:485–98. doi: 10.1038/s41577-020-00490-y
175
SakaiSLoraNEKauffmanKDDoroskyDEOhSNamasivayamSet al. Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. Mucosal Immunol. (2021) 14:1055–66. doi: 10.1038/s41385-021-00425-3
176
PahujaIVermaAGhoshalAMukhopadhyaySKumariAShajiAet al. Biapenem, a carbapenem antibiotic, elicits mycobacteria specific immune responses and reduces the recurrence of tuberculosis. Microbiol Spectr. (2023) 11. doi: 10.1128/spectrum.00858-23
177
ClarkEHVázquez de la TorreAHoshikawaTBristonT. Targeting mitophagy in Parkinson’s disease. J Biol Chem. (2021) 296:100209. doi: 10.1074/jbc.REV120.014294
178
ManzanilloPSAyresJSWatsonROCollinsACSouzaGRaeCSet al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature. (2013) 501:512–6. doi: 10.1038/nature12566
179
ChenXXuHShuXSongC-X. Mapping epigenetic modifications by sequencing technologies. Cell Death Differ. (2023). doi: 10.1038/s41418-023-01213-1
Summary
Keywords
early immunity, preclinical models, in vivo, cytokines, receptors, innate cells, trained immunity
Citation
Nieto Ramirez LM, Mehaffy C and Dobos KM (2025) Systematic review of innate immune responses against Mycobacterium tuberculosis complex infection in animal models. Front. Immunol. 15:1467016. doi: 10.3389/fimmu.2024.1467016
Received
19 July 2024
Accepted
27 December 2024
Published
30 January 2025
Volume
15 - 2024
Edited by
Styliani Karanika, Johns Hopkins Medicine, United States
Reviewed by
Elena Stylianou, University of Oxford, United Kingdom
Namrata Anand, University of Chicago Medical Center, United States
Kathirvel Maruthai, Johns Hopkins University, United States
Updates

Check for updates
Copyright
© 2025 Nieto Ramirez, Mehaffy and Dobos.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luisa Maria Nieto Ramirez, luisam@colostate.edu; Karen Marie Dobos, karen.dobos@colostate.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.